Development Research Program

发展研究计划

• 批准号: 10268767
• 负责人: WILLIAM A CLIBY
• 金额: $ 14.79万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2026-08-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10268767
• 关键词: Advisory Committees; Award; Cancer Patient; Chicago; Clinic; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Communities; Creativeness; Data; Development; Direct Costs; Disabled Persons; Disease; Extramural Activities; Facilities and Administrative Costs; Fostering; Funding; Goals; Grant; Human Resources; Individual; Institution; Intervention; Laboratory Study; Letters; Malignant neoplasm of ovary; Mayo Clinic Cancer Center; Measures; Minnesota; Minority; Monitor; Ovarian; Patient advocacy; Patients; Peer Review; Pilot Projects; Policies; Population; Population Study; Process; Program Research Project Grants; Publications; Recommendation; Research; Research Personnel; Research Project Grants; Research Support; Stimulus; System; Testing; TimeLine; Translating; Translational Research; United States National Institutes of Health; Universities; Woman; Work; anticancer research; base; clinically relevant; experience; improved; innovation; interdisciplinary collaboration; interest; originality; programs; research and development; sound; success; translational pipeline

ABTRACT – DEVELOPMENTAL RESEARCH PROGRAM (DRP) The purpose of the Developmental Research Program (DRP) in the Mayo Clinic SPORE in Ovarian Cancer is to support innovative, scientifically sound research projects from which findings can be translated into clinically relevant interventions that will reduce the burden of ovarian cancer. This program has been highly successful, with support going to 38 DRP projects in Years 6-10. Among the DRP project teams, 21 (11 funded in Years 1- 5 and 10 funded in Years 6-10) have received additional funding outside of the SPORE in Years 6-10 based on their DRP project and 5 provided data instrumental for the selection of the full research projects in this renewal. In our second funding period, the DRP generated 74 associated publications and contributed to 7 SPORE- associated clinical trials. We will build on the successes of our SPORE DRP, which has attracted investigators new to ovarian cancer research who ultimately became co-Leaders or co-Investigators of full Projects included in this SPORE application, Core co-Leaders, or were awarded NIH funding outside of the SPORE. The DRP will 1) foster innovative laboratory, population, and clinical study proposals that have strong translational potential; 2) encourage and support interdisciplinary collaboration in translational research in ovarian cancer; and 3) generate new hypotheses that can be tested in larger scale research projects or clinical trials in ovarian cancer. The DRP will provide $200,000 annually ($100,000 from the SPORE and a matching $100,000 from Mayo Clinic) to support at least 4 meritorious projects with $50,000 each to be used within one year. In addition, between August 2014 and July 2020 we raised philanthropic support for ovarian cancer research at Mayo Clinic that supported 18 DRP awards above and beyond the 20 originally projected during Years 6-10; and we will continue to seek additional support for ovarian cancer research in the years to come. Depending on the progress of any given project, the possibility of a second year of support exists via competitive review of both new and continuation projects. The DRP will continue to utilize a defined process to call for applications on an annual basis and to review submissions, utilizing the expertise of the Internal Scientific Advisory Committee, Executive Committee, Patient Advocacy Advisory Committee, and other experienced investigators as needed. Criteria for DRP awards include: The likelihood that the work will impact major challenges in ovarian cancer, scientific merit, originality, translational potential, qualifications of the key personnel, and interactivity. As experienced in our second funding period, it is anticipated that support of DRP projects through this program will generate new hypotheses that progress to full SPORE translational projects or to peer- reviewed external grant support.

分类 - 发展研究计划（DRP） 卵巢癌蛋黄酱孢子中发展研究计划（DRP）的目的是 为了支持创新，科学合理的研究项目，从中可以将发现转化为临床 相关干预措施将减少卵巢癌的燃烧。该计划非常成功， 在6 - 10年内，支持38个DRP项目的支持。在DRP项目团队中，有21个（有11年资助1- 在6 - 10年中资助的5和10）基于6 - 10年以外的孢子以外获得了额外的资金 他们的DRP项目和5个提供了​​数据工具，可用于选择此续签的完整研究项目。 在我们的第二个融资期内，DRP生成了74个相关出版物，并为7个孢子做出了贡献。 相关的临床试验。我们将以孢子DRP的成功为基础，该孢子吸引了调查人员 卵巢癌研究的新手，最终成为完整项目的共同领导者或共同研究者 在此孢子应用程序中，核心共同领导者或在孢子以外获得了NIH资金。 DRP 将1）培养具有强大翻译的创新实验室，人口和临床研究建议 潜在的; 2）鼓励和支持卵巢癌转化研究的跨学科合作； 3）产生新的假设，可以在大规模研究项目或卵巢临床试验中进行测试 癌症。 DRP每年将提供20万美元 Mayo Clinic）至少支持一年内使用50,000美元的至少4个有功项目。在 此外，在2014年8月至2020年7月之间，我们为卵巢癌研究提供了慈善支持 梅奥诊所（Mayo Clinic）在6 - 10年度最初预计的20个奖项之外，支持18个DRP奖项； 在未来的几年中，我们将继续为卵巢癌研究寻求更多支持。取决于 关于任何给定项目的进度，通过对 新项目和延续项目。 DRP将继续利用定义的过程来呼吁应用程序 每年使用内部科学咨询的专业知识，每年审查提交 委员会，执行委员会，患者倡导咨询委员会以及其他经验丰富的调查员 根据需要。 DRP奖项的标准包括：工作可能会影响主要挑战的可能性 卵巢癌，科学功绩，独创性，翻译潜力，关键人员的资格以及 互动。正如我们在第二个融资期内经验丰富的那样，可以通过 该程序将产生新的假设，这些假设发展为全孢子翻译项目或同行 审查外部赠款支持。